Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q2 2026 Earnings Presentation
16 slides from Pacira Biosciences's earnings presentation, August 2026
Slide 1: 2Q26 Earnings Presentation
2Q26 Earnings Presentation PCRX | August 2026
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information Any statements in this presentation about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “int
Slide 3: Guiding Principles: Mission and Values
GUIDING PRINCIPLES MISSION We deliver innovative, non-opioid pain therapies to transform the lives of patients. VALUES Every day, we are is the We respect the determined to foundation of diverse talent and who we are the collective power of a Better is possible. 3
Slide 4: Significant cash-generating commercial base, advancing pipeline value
SIGNIFICANT CASH-GENERATING COMMERCIAL BASE ADVANCING PIPELINE VALUE 1 2 3 4 5 More than 3 million Double-digit 5-percentage point Clinical pipeline Establishing patients treated compounded non-GAAP gross expansion with 5 partnerships per year annual growth rate margin improvement 5 novel programs i
Slide 5: 2Q26 performance reflects disciplined execution
2Q26 performance reflects disciplined execution Revenues of >$190M, driven by 4% PCRX-201 scalable commercial volume growth despite macroeconomic manufacturing process up and running; pressures weighing on hospital elective Part B of ASCEND study underway procedures Adjusted EBITDA of nearly $50M Co
Slide 6: EXPAREL well-positioned to continue outperforming elective surgery market
EXPAREL well-positioned to continue outperforming elective surgery market by advancing three key priorities Utilizing growing body Expanding patient Driving expanded of HEOR studies to 1 access by securing new 2 demonstrate value 3 utilization within fastest commercial coverage growing areas proposi
Slide 7: Expanding patient access through commercial payer wins
Expanding patient access through commercial payer wins providing separate reimbursement outside surgical bundle Covered lives expansion progress UnitedHealthcare ~40M 160M >150M ~50% of all 102M U.S. medically insured lives 2024 2025 UnitedHealthcare Additional YTD 2026 Goal recent wins Better is po
Slide 8: 2026 set to be a pivotal year as Pacira enters a data-rich period
2026 set to be a pivotal year as Pacira enters a data-rich period Product Target 2026 2027 2028+ Commercial Base Pediatric 0 to <6 PK/Safety Clinical Trial Shoulder OA Topline readout Knee OA IGOR | Capturing real-world data spanning the patient treatment journey in knee OA Innovative Pipeline Phase
Slide 9: PCRX-201: Part A of Phase 2 ASCEND study on track for topline data
PCRX-201: Part A of Phase 2 ASCEND study on track for topline data end of year Enrollment in Part B underway Part A Part B IA Corticosteroid* IA Corticosteroid* + + Group 1 PCRX-201: 1.4×1010 GC PCRX-201: 1.4×1010 GC N=15(A) N=30(B) Two-part P2 study: IA Corticosteroid* IA Corticosteroid* Adult subj
Slide 10: Increasing validation of HCAd platform's potential
Increasing validation of HCAd platform’s potential HCAd platform generating promising PCRX-201 preclinical candidates Dry eye disease PCRX-1002 Phase 1 manuscript accepted for publication in the Annals of the Rheumatic Degenerative disc disease Diseases journal PCRX-2002 PCRX-1003 Canine osteoarthri
Slide 11: High-caliber partnerships
High-caliber partnerships Extend commercial reach, improve capital efficiency and enable resource concentration on highest-priority growth opportunities Partnership to optimize business Partnership to extend commercial reach iovera° divestiture Licensing & distribution (July 2026) (January 2026) • S
Slide 12: Significant cashflow generation to advance strategy and create shareholder value
Significant cashflow generation to advance strategy and create shareholder value into and well beyond 2030 $ in M, except per share $ in M 2Q26 2026 Financial Guidance $147.8 Updated as of 2Q26 to reflect closing of the Zimmer transaction Total Revenue $735-760 $32.6 1 $6.8 Non-GAAP SG&A $310-330 To
Slide 13: Website, Investor toolkit, Social
Website Investor-toolkit Social: X Social: LinkedIn
Slide 14: Appendix
APPENDIX Better is possible. 14
Slide 15: Non-GAAP disclosure – Adjusted EBITDA
Non-GAAP disclosure – Adjusted EBITDA Better is possible. 15
Slide 16: Non-GAAP disclosure – Gross margin
Non-GAAP disclosure – Gross margin Better is possible. 16